NASDAQ:CRTXCortexyme Stock Price, Forecast & News

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRTX shares have increased by 18.9% and is now trading at $44.00. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cortexyme.

Cortexyme is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Cortexyme.

Cortexyme, Inc. (NASDAQ:CRTX) issued its earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.16. View Cortexyme's earnings history.

4 Wall Street analysts have issued 1 year price objectives for Cortexyme's shares. Their forecasts range from $14.00 to $70.00. On average, they anticipate Cortexyme's stock price to reach $44.80 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price. View analysts' price targets for Cortexyme.

News articles about CRTX stock have been trending very positive recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cortexyme earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutCortexyme.

Cortexyme saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,060,000 shares, an increase of 21.2% from the April 30th total of 1,700,000 shares. Based on an average daily trading volume, of 129,300 shares, the short-interest ratio is presently 15.9 days. Currently, 17.4% of the shares of the company are sold short. View Cortexyme's Current Options Chain.

Some companies that are related to Cortexyme include Cerner (CERN), Omnicell (OMCL), HMS (HMSY), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Vocera Communications (VCRA) and Computer Programs & Systems (CPSI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include Honeywell International (HON), AT&T (T), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Thermo Fisher Scientific (TMO) and Home Depot (HD).

(CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Cortexyme's stock is owned by a variety of retail and institutional investors. Top institutional investors include Capital Research Global Investors (8.64%), Capital International Investors (3.35%), Capital World Investors (2.53%), BlackRock Inc. (2.22%), State Street Corp (0.66%) and Geode Capital Management LLC (0.46%). Company insiders that own Cortexyme stock include David Lamond, Epiq Capital Group, Llc and Pfizer Inc. View institutional ownership trends for Cortexyme.

CRTX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Invesco Ltd., Alps Advisors Inc., Virtus ETF Advisers LLC, Alliancebernstein L.P., UBS Group AG, Legal & General Group Plc, and American International Group Inc.. View insider buying and selling activity for Cortexyme.

CRTX stock was purchased by a variety of institutional investors in the last quarter, including Capital World Investors, Pacific Heights Asset Management LLC, Capital Research Global Investors, BlackRock Inc., Capital International Investors, Geode Capital Management LLC, Ikarian Capital LLC, and State Street Corp. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc. View insider buying and selling activity for Cortexyme.

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRTX stock can currently be purchased for approximately $44.00.

Cortexyme has a market capitalization of $1.29 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 16 workers across the globe.

The official website for Cortexyme is www.cortexyme.com.

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]